U.S. markets close in 3 hours 40 minutes
  • S&P 500

    3,770.08
    +1.61 (+0.04%)
     
  • Dow 30

    31,012.70
    +88.56 (+0.29%)
     
  • Nasdaq

    12,609.61
    -113.86 (-0.89%)
     
  • Russell 2000

    2,121.39
    -25.53 (-1.19%)
     
  • Crude Oil

    66.04
    +2.21 (+3.46%)
     
  • Gold

    1,696.00
    -4.70 (-0.28%)
     
  • Silver

    25.01
    -0.45 (-1.75%)
     
  • EUR/USD

    1.1918
    -0.0061 (-0.51%)
     
  • 10-Yr Bond

    1.5640
    +0.0140 (+0.90%)
     
  • GBP/USD

    1.3808
    -0.0086 (-0.62%)
     
  • USD/JPY

    108.2840
    +0.3080 (+0.29%)
     
  • BTC-USD

    47,822.79
    -1,699.59 (-3.43%)
     
  • CMC Crypto 200

    956.25
    +13.07 (+1.39%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,864.32
    -65.79 (-0.23%)
     

Is Now An Opportune Moment To Examine Abiomed, Inc. (NASDAQ:ABMD)?

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

Let's talk about the popular Abiomed, Inc. (NASDAQ:ABMD). The company's shares led the NASDAQGS gainers with a relatively large price hike in the past couple of weeks. With many analysts covering the large-cap stock, we may expect any price-sensitive announcements have already been factored into the stock’s share price. However, what if the stock is still a bargain? Let’s examine Abiomed’s valuation and outlook in more detail to determine if there’s still a bargain opportunity.

See our latest analysis for Abiomed

Is Abiomed still cheap?

According to my price multiple model, where I compare the company's price-to-earnings ratio to the industry average, the stock currently looks expensive. I’ve used the price-to-earnings ratio in this instance because there’s not enough visibility to forecast its cash flows. The stock’s ratio of 69.97x is currently well-above the industry average of 52.83x, meaning that it is trading at a more expensive price relative to its peers. But, is there another opportunity to buy low in the future? Since Abiomed’s share price is quite volatile, this could mean it can sink lower (or rise even further) in the future, giving us another chance to invest. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.

What does the future of Abiomed look like?

earnings-and-revenue-growth
earnings-and-revenue-growth

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. Abiomed's earnings over the next few years are expected to increase by 21%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value.

What this means for you:

Are you a shareholder? It seems like the market has well and truly priced in ABMD’s positive outlook, with shares trading above industry price multiples. At this current price, shareholders may be asking a different question – should I sell? If you believe ABMD should trade below its current price, selling high and buying it back up again when its price falls towards the industry PE ratio can be profitable. But before you make this decision, take a look at whether its fundamentals have changed.

Are you a potential investor? If you’ve been keeping an eye on ABMD for a while, now may not be the best time to enter into the stock. The price has surpassed its industry peers, which means it is likely that there is no more upside from mispricing. However, the optimistic prospect is encouraging for ABMD, which means it’s worth diving deeper into other factors in order to take advantage of the next price drop.

Since timing is quite important when it comes to individual stock picking, it's worth taking a look at what those latest analysts forecasts are. Luckily, you can check out what analysts are forecasting by clicking here.

If you are no longer interested in Abiomed, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.